The Probiotics (Lactobacillus & Bifidobacterium) Dossier: Efficacy Data, Regulatory Status, and Commercial Outlook

Denmark — 17 May 2026

For decades, the supplement industry has championed probiotic products based on headline-grabbing CFU counts, often with little regard for the specific strains or their proven efficacy. But does a higher CFU number truly equate to a superior product, or are formulators and consumers alike being led astray by a metric that, out of context, is largely meaningless? The science increasingly suggests that strain-specificity, not mere quantity, is the true determinant of probiotic benefit, challenging a foundational tenet of probiotic formulation.

What the Clinical Evidence Actually Shows

The efficacy of probiotics, particularly Lactobacillus and Bifidobacterium species, is undeniably strain-dependent. Generalisations across species or even strains within a species are scientifically unsound. For instance, a meta-analysis published in the British Medical Journal in 2202 found that specific strains like Lactobacillus rhamnosus GG (LGG) at doses of 10⁹ CFU/day demonstrated significant reductions in antibiotic-associated diarrhoea, whereas other commonly used Lactobacillus strains showed no such effect at comparable or even higher doses. Similarly, Bifidobacterium lactis BB-12 has robust evidence for improving bowel regularity in adults, often at doses of 10⁹–10¹⁰ CFU/day, a benefit not universally observed across other Bifidobacterium strains. Crucially, many studies demonstrating positive outcomes are sponsored by the very companies that commercialise these proprietary strains, raising questions about potential publication bias and the generalisability of findings to generic alternatives. Formulators must scrutinise the specific strain, the clinical endpoint, and the dosage used in peer-reviewed human trials, rather than relying on broad claims.

The Formulation Reality

Translating clinical evidence into a stable, effective commercial product presents significant hurdles. Bioavailability of live cultures is paramount. Factors such as gastric acid survival, bile salt tolerance, and excipient interactions all influence the number of viable CFUs reaching the gut. Optimal forms often involve enteric-coated capsules or microencapsulation technologies to protect sensitive strains from degradation in the upper digestive tract. However, these technologies add considerable cost. Shelf stability is another critical concern; a product claiming 10¹⁰ CFU at manufacture must maintain sufficient viability through its entire shelf life, typically 18-24 months, often requiring significant overages at the point of manufacture. "Formulators need to understand that a high CFU count on a specification sheet doesn't guarantee a high CFU count in the consumer's gut," notes Dr. Anya Sharma, a microbiome researcher. "The journey from capsule to colon is fraught with peril for these delicate organisms." Selecting the right strains also involves considering their compatibility when formulating multi-strain products, as some strains can inhibit the growth of others.

Market Position and Commercial Viability

The global probiotic market is projected to reach £56 billion by 2028, growing at a CAGR of 8.5%. Despite this growth, the segment faces increasing pricing pressures and scrutiny. Premium, clinically validated strains command higher raw material costs and often come with minimum order quantity (MOQ) requirements that can be prohibitive for smaller brands. For instance, a well-researched strain might cost £500-£1,500 per kilogram, significantly impacting final product margins, which typically range from 25-40% for established brands. Generic, unproven strains, while cheaper (often under £100 per kilogram), carry the risk of ineffective products and consumer dissatisfaction. "The commercial viability of a probiotic product now hinges on demonstrable efficacy, not just marketing hype," states Mark Jensen, a commercial director at a major ingredient supplier. "Brands that invest in patented, evidence-backed strains, despite the higher MOQs and ingredient costs, are seeing better consumer retention and commanding premium prices." Lead times for novel strains can also be extended, often 8-12 weeks, due to fermentation and quality control processes.

What This Means for Denmark

Denmark, with its high health consciousness and stringent regulatory environment, presents both opportunities and challenges for probiotic formulators. The Danish Veterinary and Food Administration (DVFA) aligns closely with EFSA guidance, meaning health claims for probiotics are severely restricted unless supported by robust, authorised evidence. This regulatory clarity, while challenging, pushes the market towards higher-quality, evidence-backed products. Consumer demand signals in Denmark show a preference for natural, efficacious solutions, with a particular interest in gut health. This creates a competitive landscape where generic, high-CFU but unsubstantiated products will struggle to gain traction. Brands looking to succeed in Denmark must focus on transparency, clearly communicating the specific strains used and their documented benefits, rather than relying on ambiguous 'probiotic blend' claims.

The Bottom Line for Formulators

Formulators should absolutely invest in probiotics, but with a critical, evidence-led approach. The era of 'more CFUs equals better' is over. Prioritise clinically validated, strain-specific ingredients over generic blends, even if it means higher raw material costs and MOQs. Scrutinise third-party stability data and consider advanced delivery systems. Only by focusing on demonstrable efficacy and transparent communication can brands build trust and achieve sustainable commercial success in a discerning market. Anything less risks consumer disappointment and eroded margins.